Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis-Reference-Cited by-同舟云学术

Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis

Published:2020-11 Issue: Volume:90 Page:102086
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Desnoyers Alexandra,Nadler Michelle B.,Kumar Vikaash,Saleh Ramy,Amir Eitan

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference39 articles.

1. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015

3. Palbociclib and letrozole in advanced breast cancer;Finn;N Engl J Med,2016

4. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up;Rugo;Breast Cancer Res Treat,2019

5. Overall survival with palbociclib and fulvestrant in advanced breast cancer;Turner;N Engl J Med,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

2. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

3. Spectrum of psychiatric adverse reactions to cyclin‐dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system;CNS Neuroscience & Therapeutics;2024-07

4. Comparative efficacy and safety of CDK4/6 inhibitors combined with endocrine therapies for HR+/HER2-breast cancer: Systematic review and network meta-analysis;Heliyon;2024-06

5. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study;Expert Opinion on Drug Safety;2024-05-16